Therapeutic effects of thermotherapy combined with exercise training on physical activity in hospitalized aged patients with decompensated heart failure.

Therapeutic effects of thermotherapy combined with exercise training on physical activity in hospitalized aged patients with decompensated heart failure. - Combined effects of thermotherapy and exercise training in patients with heart failure.

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000031444

Enrollment

120

Registered

2018-04-01

Start date

2018-05-14

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hospitalized patients with heart failure

Interventions

Hyperthermia therapy using far infrared rays (One or twice treatment session a day, 5 days per week for a month or during hospitalization). It combines with ordinary cardiac rehabilitation. Only tradi

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients met all of following criterion are enrolled. 1) Written informed consent obtained from subject or legal representative. 2) >20 years of age. 3) Hospitalization for heart failure with New York Heart Association (NYHA) class 3 to 4 symptoms. 4) Heart failure defined as patients with either left ventricular ejection fraction of 40% or less, maximal oxygen consumption (peak VO2) of 80% or less, or plasma BNP levels of 80 pg/ml or less.

Exclusion criteria

Exclusion criteria: Patients met either of following criterion are not enrolled. 1) Acute inflammatory diseases such as bacterial infection or thrombophlebitis. 2) Paresthesia of legs. 3) Uncontrollable bleeding or known bleeding diathesis with active bleeding. 4) Patients with cancers. 5) Patients who have condition or factor serves as a reason to withhold hyperthermia therapy.

Design outcomes

Primary

Measure	Time frame
Peak oxygen consumption (VO2) post treatment	—

Secondary

Measure	Time frame
All values are post treatment. 1) VE/VCO2 slope 2) Anaerobic Threshold (AT) point 3) Serum IGF-1 levels 4) Serum TNF alpha levels 5) Plasma Noradrenaline levels 6) Plasma BNP levels 7) Plasma plasminogen activator inhibitor-1 levels 8) Left ventricular end-diastolic diameter by cardiac ultrasound 9) Left arterial diameter or volume by cardiac ultrasound 10) Sleep quality assessed by St. Mary's Hospital Sleep Questionnaire 11) Worsening congestive heart failure 12) Death from any cause 13) Adverse event (e.g. accidental burns, falling accident)	—

Measure

Time frame

All values are post treatment. 1) VE/VCO2 slope 2) Anaerobic Threshold (AT) point 3) Serum IGF-1 levels 4) Serum TNF alpha levels 5) Plasma Noradrenaline levels 6) Plasma BNP levels 7) Plasma plasminogen activator inhibitor-1 levels 8) Left ventricular end-diastolic diameter by cardiac ultrasound 9) Left arterial diameter or volume by cardiac ultrasound 10) Sleep quality assessed by St. Mary's Hospital Sleep Questionnaire 11) Worsening congestive heart failure 12) Death from any cause 13) Adverse event (e.g. accidental burns, falling accident)

—

Countries

Japan

Contacts

Public ContactHideyuki Kondo

Hyogo College of Medicine Sasayama Medical Center Department of General Medicine and Community Health Science

hi-kondo@hyo-med.ac.jp+81-79-552-1181

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026